Shanghai Bio-heart Biological (2185) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Shanghai Bio-heart Biological stock HK$0.93, price HK$0.90, upside +3.0%, quality 43 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Shanghai Bio-heart Biological
2185 · HKThe stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range HK$0.9000 – HK$2,939 · fair‑value band HK$0.6956 – HK$1.16 · the HK$0.9000 price screens below the HK$0.9274 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Every Wednesday you see whether Shanghai Bio-heart Biological is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Shanghai Bio-heart Biological Technology Co., Ltd., together with its subsidiaries, engages in the research, development, and commercialization of invasive treatment products in China.
Show moreShow less
The company develops Bioheart, a bioresorbable scaffolds system, which is in registration stage for percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis, a renal denervation system, which is in clinical stage for the treatment of uncontrolled hypertension and resistant hypertension; and DCB, a sirolimus drug coated balloon catheter, which is in clinical stage for the treatment of instent restenosis.
It is also involved in local administration and manufacturing services. The company was founded in 2014 and is headquartered in Shanghai, China.
Stock analysis
Shanghai Bio-heart Biological (2185) currently trades at HK$0.9000, while our estimate is HK$0.9274, so the stock looks roughly fairly valued today (gap 2.9%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: HK$0.6956 (bear) to HK$1.16 (bull), the price of HK$0.9000 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Shanghai Bio-heart Biological reported revenue of 43.8M CNY in FY2025 versus 0 CNY in FY2021. Reported net income was −68.2M CNY in FY2025.
Key figures
Market cap HK$222M (≈ $28.4M) Micro · P/S ratio 6.27 · Return on equity −12.2% · Return on assets (EBIT) −20.7% (5-year average) · Operating margin −261% · Revenue (TTM) 38.4M CNY · Revenue growth (YoY) −31.1% · Free cash flow −72.9M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 88% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 3%, 2185 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch 2185, get fair value alerts →
Compare Shanghai Bio-heart Biological with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 400 stocks
Valuation Multiplesvs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/B ratio by industry
- Net margin by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Boston Scientific Corporation BSX | $44.34 | $49.64 | +12% | vs 2185 |
| Stryker Corporation SYK | $309.64 | $343.63 | +11% | vs 2185 |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥179.40 | ¥197.34 | +10% | vs 2185 |
| STERIS plc STE | $264.32 | $281.90 | +7% | vs 2185 |
| DexCom, Inc DXCM | $83.33 | $88.38 | +6% | vs 2185 |
| GE HealthCare Technologies Inc GEHC | $83.02 | $69.92 | −16% | vs 2185 |
| Edwards Lifesciences Corporation EW | $107.15 | $81.94 | −24% | vs 2185 |
| Medtronic plc MDT | $102.86 | $74.90 | −27% | vs 2185 |
| Abbott Laboratories, ABT | $108.52 | $75.28 | −31% | vs 2185 |
| Koninklijke Philips N.V PHIA | €27.43 | €15.23 | −44% | vs 2185 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Shanghai Bio-heart Biological (2185) overvalued or undervalued?
What is the fair value of 2185?
What is the quality score of 2185?
What is the price target for Shanghai Bio-heart Biological (2185)?
What is the Shanghai Bio-heart Biological stock forecast for 2026?
What is the revenue of Shanghai Bio-heart Biological (2185)?
What is the intrinsic value of Shanghai Bio-heart Biological (2185)?
Is Shanghai Bio-heart Biological stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 2185?
How much is Shanghai Bio-heart Biological worth?
What do the bullish and bearish scenarios say about 2185?
How solid is the balance sheet of Shanghai Bio-heart Biological (2185)?
How far is 2185 from its 52-week high?
Which stocks are comparable to Shanghai Bio-heart Biological?
Is Shanghai Bio-heart Biological stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Shanghai Bio-heart Biological (2185)?
What should I pay attention to with Shanghai Bio-heart Biological right now?
Key figures of Shanghai Bio-heart Biological
How large is the market capitalisation of Shanghai Bio-heart Biological (2185)?
What is the P/S ratio of Shanghai Bio-heart Biological (2185)?
What is the return on equity of Shanghai Bio-heart Biological (2185)?
What is the EBIT return on assets of Shanghai Bio-heart Biological (2185)?
What is the operating margin of Shanghai Bio-heart Biological (2185)?
How fast is revenue growing at Shanghai Bio-heart Biological (2185)?
How much free cash flow does Shanghai Bio-heart Biological (2185) generate?
How much net cash does Shanghai Bio-heart Biological (2185) hold?
Watch Shanghai Bio-heart Biological in the live analysis
One click puts Shanghai Bio-heart Biological on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.